Telix Pharmaceuticals Limited is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. The company concentrates on precision oncology, employing a theranostic approach that pairs diagnostic imaging agents with therapeutic counterparts to enable personalized cancer care. Its activities span research, clinical development, manufacturing, and commercialization of radiopharmaceutical products targeting conditions such as prostate cancer, kidney cancer, glioma, and other solid tumors. Telix operates in multiple regions, with headquarters in Melbourne, Australia, and a substantial presence in the United States, Europe, and Asia Pacific, supporting a worldwide network of clinical sites and distribution partners.

Telix generates revenue primarily from the sale of its diagnostic imaging agents, including Illuccix and Gozellix, which are approved for prostate cancer imaging in multiple jurisdictions. During the fiscal year 2025, the Precision Medicine business generated revenue of $621.9 million, largely driven by sales of these two products. The company also anticipates future income from the commercialization of its therapeutic product candidates as they receive regulatory approval, and from its MedTech offerings such as the SENSEI radio-guided surgery system. Additionally, revenue is derived from contract manufacturing services, licensing agreements, and the provision of radiopharmaceutical production capabilities to third-party partners.

The company operates through the following segments: Therapeutics (Tx), Precision Medicine (Px), MedTech and Telix Manufacturing Solutions (TMS). These segments reflect the organization’s focus on drug development, commercialization, surgical technology, and manufacturing infrastructure, while geographic responsibilities are managed within the Precision Medicine and MedTech units.

• Therapeutics: This segment focuses on developing targeted radionuclide therapies for urologic and neurologic oncology, as well as other solid tumors, with pipeline candidates such as TLX591-Tx (lutetium-177 labeled rosopatamab) for prostate cancer, TLX250-Tx (lutetium-177 labeled girentuximab) for kidney cancer, TLX101-Tx (iodine-131 labeled) for glioma, and TLX090-Tx (samarium-153 labeled) for bone pain palliation.

• Precision Medicine: This segment serves as the commercial arm, bringing diagnostic imaging solutions to market and expanding into new geographies and indications, with products including Illuccix (gallium-68 PSMA-11), Gozellix (gallium-68 PSMA-11), TLX250-Px (zirconium-89 labeled girentuximab) for kidney cancer imaging, and TLX101-Px (fluorine-18 labeled FET) for glioma imaging.

• MedTech: This segment advances surgical solutions and digital products that power precision medicines and therapeutics, exemplified by the SENSEI radio-guided probe for intraoperative detection, AI-powered imaging tools designed to enhance workflow efficiency, and digital platforms that support treatment planning and patient selection.

• Telix Manufacturing Solutions: This segment operates a global network of manufacturing and distribution facilities, including radiopharmacies, cyclotron sites in Belgium, the United States, Japan, and Australia, and GMP-capable production sites that ensure reliable supply and delivery of radiopharmaceutical products to patients worldwide, supporting both clinical trials and commercial scale-up.

Telix occupies a leading position in the radiopharmaceutical industry, particularly in the theranostics space, where it differentiates itself through deep expertise in radiopharmaceutical drug development, a broad pipeline spanning the cancer care continuum, and a vertically integrated supply chain that supports end-to-end product delivery. The company’s competitive advantages include its antibody-based radiopharmaceutical platform, proprietary linker technologies such as the RADmAb engineering, and a global manufacturing footprint that enables rapid scale-up of new products. Key competitors include Novartis, Lantheus Holdings, Bayer AG, and other firms developing PSMA-targeted therapies and imaging agents, yet Telix’s combination of innovative pipeline, integrated infrastructure, and focus on unmet medical needs provides a distinct edge in the market.

Telix serves hospitals, health systems, clinics, and nuclear medicine departments that utilize its diagnostic and therapeutic radiopharmaceuticals, with specific distribution partners such as Cardinal Health, PharmaLogic Holdings, Jubilant Pharma, and various regional radiopharmacy networks across the United States, Europe, and Asia Pacific. The company’s products are administered to patients undergoing cancer imaging or treatment, supporting a diverse oncology customer base that includes individuals with prostate cancer, kidney cancer, glioma, and other solid tumors. In addition, Telix collaborates with research institutions and clinical trial sites to advance its pipeline and bring new therapies to market.